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reamble
eeping pace with the stream of new data and evolving
idence on which guideline recommendations are based is
ongoing challenge to timely development of clinical
actice guidelines. In an effort to respond promptly to new
idence, the American College of Cardiology Foundation
CCF)/American Heart Association (AHA) Task Force on
ractice Guidelines (Task Force) has created a “focused up-
te” process to revise the existing guideline recommendations
at are affected by evolving data or opinion. New evidence is
viewed in an ongoing fashion to more efficiently respond to
portant science and treatment trends that could have a major
pact on patient outcomes and quality of care. Evidence is
viewed at least twice a year, and updates are initiated on an
-needed basis and completed as quickly as possible while
aintaining the rigorous methodology that the ACCF and AHA
ve developed during their partnership of 20 years. coThese focused updates are prompted following a thorough
view of late-breaking clinical trials presented at national
d international meetings, in addition to other new published
ta deemed to have an impact on patient care (Section 1.1,
ethodology and Evidence Review”). Through a broad-
sed vetting process, the studies included are identified as
ing important to the relevant patient population. The
cused update is not intended to be based on a complete
terature review from the date of the previous guideline
blication but rather to include pivotal new evidence that
ay affect changes to current recommendations.
Specific criteria or considerations for inclusion of new data
clude the following:
publication in a peer-reviewed journal;
large, randomized, placebo-controlled trial(s);
nonrandomized data deemed important on the basis of
results affecting current safety and efficacy assumptions,
including observational studies and meta-analyses;
strength/weakness of research methodology and findings;
likelihood of additional studies influencing current find-
ings;
impact on current and/or likelihood of need to develop new
performance measure(s);
request(s) and requirement(s) for review and update from the
practice community, key stakeholders, and other sources free
of industry relationships or other potential bias;
number of previous trials showing consistent results; and
need for consistency with a new guideline or guideline
updates or revisions.
In analyzing the data and developing recommendations and
pporting text, the writing group uses evidence-based meth-
ologies developed by the Task Force (1). The Class of
ecommendation (COR) is an estimate of the size of the
eatment effect, with consideration given to risks versus
nefits, as well as evidence and/or agreement that a given
eatment or procedure is or is not useful/effective and in
me situations may cause harm. The Level of Evidence
OE) is an estimate of the certainty or precision of the
eatment effect. The writing group reviews and ranks evi-
nce supporting each recommendation, with the weight of
idence ranked as LOE A, B, or C, according to specific
finitions that are included in Table 1. Studies are identified
observational, retrospective, prospective, or randomized,
appropriate. For certain conditions for which inadequate
ta are available, recommendations are based on expert
nsensus and clinical experience and are ranked as LOE C.
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October 2, 2012:1297–1313 2012 Device-Based Therapy Guideline Focused Updatehen recommendations at LOE C are supported by historical
inical data, appropriate references (including clinical re-
ews) are cited if available. For issues for which sparse data
e available, a survey of current practice among the clini-
ans on the writing group is the basis for LOE C recommen-
tions, and no references are cited. The schema for COR and
OE is summarized in Table 1, which also provides sug-
sted phrases for writing recommendations within each
OR. A new addition to this methodology is separation of the
lass III recommendations to delineate whether the recom-
endation is determined to be of “no benefit” or is associated
ith “harm” to the patient. In addition, in view of the
ble 1. Applying Classification of Recommendations and Level
A recommendation with Level of Evidence B or C does not imply that the reco
not lend themselves to clinical trials. Although randomized trials are unavaila
eful or effective.
Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.creasing number of comparative effectiveness studies, com- tirator verbs and suggested phrases for writing recommen-
tions for the comparative effectiveness of one treatment or
rategy versus another have been added for COR I and IIa,
OE A or B only.
In view of the advances in medical therapy across the
ectrum of cardiovascular diseases, the Task Force has
signated the term guideline-directed medical therapy
DMT) to represent optimal medical therapy as defined by
CCF/AHA guideline (primarily Class I)–recommended
erapies. This new term, GDMT, will be used herein and
roughout all future guidelines.
Because the ACCF/AHA practice guidelines address pa-
ence
ation is weak. Many important clinical questions addressed in the guidelines
re may be a very clear clinical consensus that a particular test or therapy is
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involveof Evid
mmend
ble, the
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merica are discussed in the text without a specific COR. For
udies performed in large numbers of subjects outside North
merica, each writing group reviews the potential impact of
fferent practice patterns and patient populations on the
eatment effect and relevance to the ACCF/AHA target
pulation to determine whether the findings should inform a
ecific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches to the diag-
sis, management, and prevention of specific diseases or
nditions. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment about care of a particular patient must be
ade by the healthcare provider and patient in light of all the
rcumstances presented by that patient. As a result, situations
ay arise in which deviations from these guidelines may be
propriate. Clinical decision making should consider the
ality and availability of expertise in the area where care is
ovided. When these guidelines are used as the basis for
gulatory or payer decisions, the goal should be improve-
ent in quality of care. The Task Force recognizes that
tuations arise in which additional data are needed to inform
tient care more effectively; these areas will be identified
ithin each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect outcomes, physicians and other healthcare
oviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and life-
yles. In addition, patients should be informed of the risks,
nefits, and alternatives to a particular treatment and should
involved in shared decision making whenever feasible,
rticularly for COR IIa and IIb, for which the benefit-to-risk
tio may be lower.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
industry relationships or personal interests among the
embers of the writing group. All writing group members
d peer reviewers of the guideline are required to disclose all
rrent healthcare-related relationships, including those ex-
ting 12 months before initiation of the writing effort. In
ecember 2009, the ACCF and AHA implemented a new
licy for relationships with industry and other entities (RWI)
at requires the writing group chair plus a minimum of 50%
the writing group to have no relevant RWI (Appendix 1
cludes the ACCF/AHA definition of relevance). These
atements are reviewed by the Task Force and all members
ring each conference call and/or meeting of the writing
oup and are updated as changes occur. All guideline
commendations require a confidential vote by the writing
oup and must be approved by a consensus of the voting
embers. Members are not permitted to draft or vote on any
xt or recommendations pertaining to their RWI. Members
ho recused themselves from voting are indicated in the list
writing group members, and specific section recusals are
ted in Appendix 1. Authors’ and peer reviewers’ RWI (Hrtinent to this guideline are disclosed in Appendixes 1 and
respectively. Additionally, to ensure complete transparency,
riting group members’ comprehensive disclosure informa-
n—including RWI not pertinent to this document—is avail-
le as an online supplement. Comprehensive disclosure infor-
ation for the Task Force is also available online at www.
rdiosource.org/ACC/About-ACC/Leadership/Guidelines-and-
ocuments-Task-Forces.aspx. The work of the writing group is
pported exclusively by the ACCF, AHA, and the Heart
hythm Society (HRS) without commercial support. Writing
oup members volunteered their time for this activity.
In an effort to maintain relevance at the point of care for
acticing physicians, the Task Force continues to oversee an
going process improvement initiative. As a result, in
sponse to pilot projects, several changes to these guidelines
ill be apparent, including limited narrative text, a focus on
mmary and evidence tables (with references linked to
stracts in PubMed), and more liberal use of summary
commendation tables (with references that support LOE) to
rve as a quick reference.
In April 2011, the Institute of Medicine released 2 reports:
inding What Works in Health Care: Standards for System-
ic Reviews and Clinical Practice Guidelines We Can Trust
,3). It is noteworthy that the ACCF/AHA practice guide-
nes were cited as being compliant with many of the
andards that were proposed. A thorough review of these
ports and our current methodology is under way, with
rther enhancements anticipated.
The recommendations in this focused update are consid-
ed current until they are superseded in another focused
date or the full-text guideline is revised. Guidelines are
ficial policy of both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
ate-breaking clinical trials presented at the annual scientific
eetings of the ACC, AHA, HRS, and European Society of
ardiology (2008 through 2010), as well as other selected
ta reported through January 2012, were reviewed by the
ideline writing group along with the Task Force and other
perts to identify trials and other key data that might affect
ideline recommendations. On the basis of the criteria and
nsiderations noted previously (Preamble), recently pub-
shed trial data and other clinical information were consid-
ed important enough to prompt a focused update of the
CC/AHA/HRS 2008 Guidelines for Device-Based Ther-
y of Cardiac Rhythm Abnormalities” (4).
To provide clinicians with a comprehensive set of data, the
solute risk difference and number needed to treat or harm,
they were published and their inclusion was deemed
propriate, are provided in the guideline, along with confi-
nce intervals (CIs) and data related to the relative treatment
fects, such as odds ratio, relative risk (RR), hazard ratio
R), or incidence rate ratio.
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uidelines for Device-Based Therapy of Cardiac Rhythm
bnormalities” for policy on clinical areas not covered by the
cused update (4). The individual recommendations in this
cused update will be incorporated into future revisions or
dates of the full-text guideline.
.2. Organization of the Writing Group
or this focused update, selected members of the 2008
evice-Based Therapy (DBT) Writing Committee were in-
ted to participate on the basis of areas of expertise,
quirements for committee rotation, and the current RWI
licy; those who agreed are referred to as the 2012 Focused
pdate Writing Group. The HRS was invited to be a partner
this focused update and has provided representation. The
riting group also included representatives from the Ameri-
n Association for Thoracic Surgery, Heart Failure Society
America, and Society of Thoracic Surgeons.
.3. Document Review and Approval
his document was reviewed by 2 official reviewers each
minated by the ACCF, AHA, and HRS, as well as 1
viewer each from the American Association for Thoracic
urgery, Heart Failure Society of America, and Society of
horacic Surgeons, and 21 individual content reviewers. All
formation on reviewers’ RWI was collected and distributed
the writing group and is published in this document
ppendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF, AHA, and HRS and was
dorsed by the American Association for Thoracic Surgery,
eart Failure Society of America, and Society of Thoracic
urgeons.
.4. Scope of the Focused Update
tudies relevant to the management of patients treated with
BT for cardiac rhythm abnormalities were identified and
viewed as described previously in Section 1.1, “Methodol-
y and Evidence Review.” On the basis of these data, the
riting group determined that updates to the 2008 guideline
ere necessary for cardiac resynchronization therapy (CRT)
d device follow-up.
Many clinical circumstances come into question in daily
actice as to the appropriate use of implantable cardioverter-
fibrillator (ICD)/CRT devices. Many of these clinical
enarios are both common and of great importance but have
t or cannot be addressed by multicenter clinical trials, so
any of these will be addressed in the “Appropriate Use
riteria (AUC) for Implantable Cardioverter-Defibrillators
d Cardiac Resynchronization Therapy” document that is
rrently in development. Unlike comprehensive guidelines,
UC documents blend evidence-based information and clin-
al experience that can help guide allocation of healthcare
sources, and they focus on the most common patient
enarios for which procedures may be considered. The AUC
cument will help define when it is reasonable to perform a
ocedure and, importantly, when it is not reasonable. Some
the scenarios included in the AUC may be outside
ideline indications. As such, AUC are complementary toidelines and should be used in conjunction with them for
termining patient care. Furthermore, the ACCF and AHA
e currently undertaking a revision of the guidelines for
anagement of heart failure (HF). The DBT and HF guide-
ne writing committees have worked to maintain concor-
nce on the recommendations with regard to indications for
RT.
The writing group also thoroughly reviewed the following
ctions from the 2008 DBT guideline (4) and determined
at although some new information may be available, the
commendations remain current.
Hypertrophic Cardiomyopathy—The management of
hypertrophic cardiomyopathy is addressed in the “2011
ACCF/AHA Guideline for the Diagnosis and Treatment of
Hypertrophic Cardiomyopathy” (5). In that document, the
indications for ICDs have been modified on the basis of
reassessment of significance of risk factors. The present
writing group did not analyze the source documents that
led to these changes and refer the reader to the ACCF/
AHA Guideline for full discussion of ICDs in hypertro-
phic cardiomyopathy.
ArrhythmogenicRightVentricularDysplasia/Cardiomyo-
pathy—The writing group reviewed all published evidence
since the publication of the 2008 DBT guideline related to
arrhythmogenic right ventricular dysplasia/cardiomyopathy
and determined that no changes to the current recommenda-
tions for ICD indications were warranted.
Genetic Arrhythmia Syndromes—The writing group
acknowledges that recent guidelines and data suggest
that there may be a limited role for primary-prevention
ICDs in individuals with a genetically confirmed diag-
nosis of long QT but without symptoms (6 – 8). Never-
theless, it is the consensus of this writing group that
until more definitive trials or studies are completed,
further refinement of criteria for ICD implantation in
this patient group would not be appropriate. Therefore,
the class of recommendations for ICD implantation in
asymptomatic patients with a genetically confirmed
mutation will remain unchanged.
Congenital Heart Disease—As with other forms of
structural heart disease, there has been increased use of
ICDs for primary prevention of sudden cardiac death in
patients with congenital heart disease (4,9). Although
randomized clinical trials have not been performed, mul-
tiple observational studies have consistently reported that
systemic ventricular dysfunction in patients with congen-
ital heart disease is the risk factor most predictive of
subsequent sudden cardiac death or appropriate ICD rescue
(10–12). These studies support consideration of an ex-
panded role of ICDs in future revisions of the guideline,
provided that consistent benefit with the use of ICDs in
patients with congenital heart disease and advanced ven-
tricular dysfunction is demonstrated. Nevertheless, the
current recommendations are not changed at this time.
There remain insufficient data to make specific recommen-
dations about CRT in patients with congenital heart
disease (13).
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viewed all published evidence since the publication of the
2008 DBT guideline related to primary electrical disease
and determined that no changes were warranted in the
current recommendations for ICD indications with regard
to idiopathic ventricular fibrillation, short-QT syndrome,
Brugada syndrome, and catecholaminergic polymorphic
ventricular tachycardia.
Terminal Care—Patients with cardiovascular implant-
able electronic devices (CIEDs) are living longer, with
more surviving to develop comorbid conditions such as
dementia or malignancy that may ultimately define their
clinical course. This was recognized in the terminal care
section of the 2008 DBT guideline. Recommendations
on management of CIEDs in patients nearing end of life
or requesting withdrawal of therapy were expanded
upon in 2 subsequent HRS expert consensus statements
in an effort to provide guidance to caregivers dealing
with this increasingly prevalent and difficult issue
(14,15).
. Indications for Pacing
.4. Pacing for Hemodynamic Indications
lthough most commonly used to treat or prevent abnormal
ythms, pacing can alter the activation sequence in the paced
ambers, influencing regional contractility and hemodynam-
s. These changes are frequently insignificant clinically but
n be beneficial or harmful in some conditions. Pacing to
crease symptoms for patients with obstructive hypertrophic car-
omyopathy is discussed separately in the full-text guideline,
ction 2.4.2, “Obstructive Hypertrophic Cardiomyopathy.”
.4.1. Cardiac Resynchronization Therapy
ee Table 2 and the Online Data Supplement for additional
ta on the trials that comprise the basis for the recommen-
tions in this focused update.)
The present document proposes several changes in recom-
endations for CRT, compared with the 2008 document. The
ost significant changes are 1) limitation of the Class I indica-
n to patients with QRS duration 150 ms; 2) limitation of
e Class I indication to patients with left bundle-branch
ock (LBBB) pattern; 3) expansion of Class I indication to
ew York Heart Association (NYHA) class II (and with
BBB with QRS duration 150 ms); and 4) the addition of
Class IIb recommendation for patients who have left
ntricular ejection fraction (LVEF) 30%, ischemic etiol-
y of HF, sinus rhythm, LBBB with a QRS duration 150
s, and NYHA class I symptoms. These changes may have
portant implications for patient selection in clinical prac-
ce, and the justification for these changes is discussed in the
llowing paragraphs.
Progression of left ventricular (LV) systolic dysfunction to
inical HF is frequently accompanied by impaired electro-
echanical coupling, which may further diminish effective
ntricular contractility. The most common disruptions are
olonged atrioventricular conduction (first-degree atrioven-
icular block) and prolonged interventricular conduction,
ost commonly LBBB. Prolonged interventricular and intra- inntricular conduction causes regional mechanical delay
ithin the left ventricle that can result in reduced ventricular
stolic function, altered myocardial metabolism, functional
itral regurgitation, and adverse remodeling with ventricular
latation (31). Prolongation of the QRS duration occurs in
proximately one third of patients with advanced HF (32,33)
d has been associated with ventricular electromechanical
lay (“dyssynchrony”), as identified by multiple sophisti-
ted echocardiographic indices. QRS duration and dyssyn-
rony both have been identified as predictors of worsening
F, sudden cardiac death, and total death (34).
Modification of ventricular electromechanical delay with
ultisite ventricular pacing (commonly called “biventricular
cing” or CRT) can improve ventricular systolic function,
duce metabolic costs, ameliorate functional mitral regurgi-
tion, and, in some patients, induce favorable remodeling
ith reduction of cardiac chamber dimensions (35–37).
unctional improvement has been demonstrated for exercise
pacity, with peak oxygen consumption in the range of 1 to
mL/kg/min and a 50- to 70-meter increase in 6-minute
alking distance, as well as a 10-point or greater reduction of
F symptoms on the 105-point Minnesota Living with Heart
ailure scale (16,38,39).
Meta-analyses of initial clinical experiences and larger
bsequent trials of CRT confirmed an approximately 30%
crease in hospitalizations and a mortality rate benefit of
% to 36% (40). In the COMPANION (Comparison of
edical Therapy, Pacing, and Defibrillation in Heart Failure)
ial (NYHA class III/IV HF, QRS duration 120 ms, and
VEF35% on GDMT), GDMT was compared to CRT pacing
erapy without backup defibrillation (CRT-Pacemaker) and to
RT therapy with defibrillation backup (CRT-D) (17). Both
RT-Pacemaker and CRT-D reduced the risk of the
imary composite endpoint by approximately 20% as
mpared with GDMT alone. CRT-D reduced the mortal-
y rate by 36% compared with medical therapy, but there
as insufficient evidence to conclude that CRT-Pacemaker
as inferior to CRT-D. The CARE-HF (Cardiac Resyn-
ronization in Heart Failure) trial (18) limited subjects to
QRS duration 150 ms (89% of patients) or QRS
ration 120 to 150 ms with echocardiographic evidence
dyssynchrony (11% of patients). It was the first study to
ow a significant (36%) reduction in death rate for
synchronization therapy unaccompanied by backup de-
brillation compared with GDMT (18).
In the present document, we give a Class I recommenda-
on for CRT in patients with QRS duration 150 ms. The
fferential classification seen in this document related to
RS duration is based on the results of multiple analyses of
RT benefit. The prevalence of mechanical dyssynchrony has
en documented in 40% of patients with dilated cardio-
yopathy and QRS duration 120 ms, and is as high as 70%
ong patients with QRS duration 150 ms and intraven-
icular mechanical delay, as identified by several echocar-
ographic techniques (34,41). However, the aggregate clinical
perience has consistently demonstrated that a significant
inical benefit from CRT is greatest among patients with QRS
ration 150 ms (42,43). In a meta-analysis of 5 trials
volving 6,501 patients, CRT significantly decreased the pri-
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RS duration 150 ms (HR: 0.58; 95% CI: 0.50 to 0.68;
0.00001) but not in patients with QRS duration 150 ms
R: 0.95; 95% CI: 0.83 to 1.10; p0.51) (42). In addition,
bgroup analyses from several studies have suggested that a
RS duration 150 ms is a risk factor for failure to respond to
RT therapy (43,44). The observed differential benefit of CRT
as seen across patients in NYHA classes I through IV. It has
t been possible to reliably identify those with shorter QRS
rations who may benefit. Patients with shorter QRS durations
ho otherwise qualify for CRT are afforded Class II recommen-
tions in these guidelines.
An additional difference in the present document compared
ith the 2008 DBT guideline (4) is the limitation of the
commendation for Class I indication to patients with LBBB
ttern as compared to those with non-LBBB. For patients
ith QRS duration 120 ms who do not have a complete
ble 2. Recommendations for CRT in Patients With Systolic Hea
2012 DBT Focused Update Recommendations
ass I
1. CRT is indicated for patients who have LVEF less than or equal to 35%, s
LBBB with a QRS duration greater than or equal to 150 ms, and NYHA cl
ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class
Level of Evidence: B for NYHA class II (20,21))
ass IIa
1. CRT can be useful for patients who have LVEF less than or equal to 35%
rhythm, LBBB with a QRS duration 120 to 149 ms, and NYHA class II, III,
ambulatory IV symptoms on GDMT (16–18,20–22). (Level of Evidence: B)
2. CRT can be useful for patients who have LVEF less than or equal to 3
rhythm, a non-LBBB pattern with a QRS duration greater than or equa
ms, and NYHA class III/ambulatory class IV symptoms on GDMT (16–1
(Level of Evidence: A)
3. CRT can be useful in patients with atrial fibrillation and LVEF less than or
35% on GDMT if a) the patient requires ventricular pacing or otherwise m
criteria and b) AV nodal ablation or pharmacologic rate control will allow
ventricular pacing with CRT (23–26,26a,48). (Level of Evidence: B)
4. CRT can be useful for patients on GDMT who have LVEF less than or
35% and are undergoing new or replacement device placement with
anticipated requirement for significant (40%) ventricular pacing (25,
(Level of Evidence: C)
ass IIb
1. CRT may be considered for patients who have LVEF less than or equa
ischemic etiology of heart failure, sinus rhythm, LBBB with a QRS dur
greater than or equal to 150 ms, and NYHA class I symptoms on GDM
(Level of Evidence: C)
2. CRT may be considered for patients who have LVEF less than or equal to
rhythm, a non-LBBB pattern with QRS duration 120 to 149 ms, and NYHA
III/ambulatory class IV on GDMT (21,30). (Level of Evidence: B)
3. CRT may be considered for patients who have LVEF less than or equal to
rhythm, a non-LBBB pattern with a QRS duration greater than or equal to
and NYHA class II symptoms on GDMT (20,21). (Level of Evidence: B)
ass III: No Benefit
1. CRT is not recommended for patients with NYHA class I or II symptoms a
LBBB pattern with QRS duration less than 150 ms (20,21,30). (Level of E
2. CRT is not indicated for patients whose comorbidities and/or frailty limit s
good functional capacity to less than 1 year (19). (Level of Evidence: C)
See Appendix 3, “Indications for CRT Therapy—Algorithm.”
CRT indicates cardiac resynchronization therapy; DBT, device-based therapy; G
ntricular ejection fraction; and NYHA, New York Heart Association.BBB (non-LBBB patterns), evidence for benefit with CRT (2less compelling than in the presence of LBBB (45–47). The
pact of the specific QRS morphology on clinical event
duction with CRT was evaluated in a meta-analysis of 4
inical trials including 5,356 patients (43). In those with
BBB, CRT significantly reduced composite adverse clinical
ents (RR: 0.64; 95% CI: 0.52 to 0.77; p0.00001). No
nefit was observed for patients with non-LBBB conduction
normalities (RR: 0.97; 95% CI: 0.82 to 1.15; p0.75).
pecifically, there was no benefit in patients with right
ndle-branch block (RR: 0.91; 95% CI: 0.69 to 1.20;
0.49) or nonspecific intraventricular conduction delay
R: 1.19; 95% CI: 0.87 to 1.63; p0.28). Overall, the
fference in effect of CRT between LBBB versus non-LBBB
tients was highly statistically significant (p0.0001) (43).
evertheless, other studies have shown that CRT is more likely
be effective in patients with advanced HF and non-LBBB
orphologies if they have a markedly prolonged QRS duration
ure
Comments
thm,
I, or
–19);
Modified recommendation (specifying CRT in patients with LBBB
of 150 ms; expanded to include those with NYHA class II
symptoms).
New recommendation
us New recommendation
o
T
0%
Modified recommendation (wording changed to indicate benefit
based on ejection fraction rather than NYHA class; level of
evidence changed from C to B).
Modified recommendation (wording changed to indicate benefit
based on ejection fraction and need for pacing rather than
NYHA class); class changed from IIb to IIa).
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ore, patients with QRS prolongation due to frequent right
ntricular apical pacing may benefit from CRT when other
iteria for CRT are met (23,25,48). No large trial has yet
monstrated clinical benefit among patients without QRS
olongation, even when they have been selected with echocar-
ographic measures of dyssynchrony (49).
The observed heterogeneity of response even among those
ho would appear to be excellent candidates for CRT also may
sult from factors such as suboptimal lead location and the
cation of conduction block from fibrosis in relation to the
cing site. Several recent studies have emphasized the impor-
nce of LV lead placement. For example, wider LV–right
ntricular lead separation has been shown to provide better
sults (50). A subanalysis of MADIT-CRT (Multicenter Auto-
atic Defibrillator Implantation Trial with Cardiac Resynchro-
zation Therapy) (20) showed that an apical LV lead position,
compared with a basal or midventricular position, resulted in
significant increased risk for HF or death (51).
Clinical trials of resynchronization included mainly pa-
ents in sinus rhythm. However, prospective experience
ong patients with permanent atrial fibrillation and with
creased LV systolic function suggests that benefit may
sult from biventricular pacing when the QRS duration is
120 ms, although it may be most evident in patients in
hom atrioventricular nodal ablation has been performed,
ch that right ventricular pacing is obligate (24,26,52). The
nefit of CRT in patients with atrial fibrillation is more
onounced in those with depressed ejection fraction (25).
imilarly, patients receiving prophylactic ICDs often evolve
ogressively to dominant ventricular pacing, which may
flect both intrinsic chronotropic incompetence and aggres-
ve up-titration of beta-adrenergic–blocking agents.
When device implantation or reimplantation is being con-
dered for patients who require ventricular pacing, it is
udent to recall the results of the DAVID (Dual Chamber
d VVI Implantable Defibrillator) trial (53). In this trial,
al-chamber rate-responsive pacing increased HF admis-
ons and mortality rate as compared to sinus rhythm. A cutoff
approximately 40% right ventricular pacing was seen as
leterious (54). Similarly, in a substudy from MADIT-II
ulticenter Automatic Defibrillator Implantation Trial II),
tients who were right ventricular paced 50% of the time
d a higher rate of new or worsened HF than those right
ntricular paced 50% of the time (55).
The major experience with resynchronization derives from
tients with NYHA class III symptoms of HF and LVEF
35%. Patients with NYHA class IV symptoms of HF have
counted for only 10% of all patients in clinical trials of
synchronization therapy. These patients were highly selected
bulatory outpatients who were taking oral medications and
d no history of recent hospitalization (56). Although a benefit
s occasionally been described in patients with more severe
ute decompensation that required brief positive intravenous
otropic therapy to aid diuresis, CRT is not generally used as a
escue therapy” for such patients. Patients with dependence on
travenous inotropic therapy, refractory fluid retention, or ad- clnced chronic kidney disease represent the highest-risk popu-
tion for complications of any procedure and for early death
ter hospital discharge, and they are also unlikely to receive a
eaningful mortality risk benefit from concomitant defibrillator
erapy (19,57).
Patients with NYHA class IV HF symptoms who derive
nctional benefit from resynchronization therapy may return
a better functional status, in which prevention of sudden
ath becomes a relevant goal. Even among the selected
YHA class IV patients identified within the COMPANION
ial (17), there was no difference in 2-year survival rate
tween the CRT patients with and without backup defibril-
tion, although more of the deaths in the CRT-Pacemaker
oup were classified as sudden deaths (56).
Perhaps the most significant changes in the present docu-
ent compared to the 2008 DBT Guideline (4) are the
pansion of the Class I recommendation for CRT to include
tients with LBBB, QRS duration 150 ms, and NYHA
ass II and the addition of a Class IIb recommendation for
tients who have LVEF 30%, ischemic etiology of HF,
nus rhythm, LBBB with a QRS duration of 150 ms, and
YHA class I symptoms. These recommendations are based
4 studies in which CRT was evaluated in patients with
inimal or mild symptoms of HF in the setting of low LVEF.
hese include MADIT-CRT, RAFT, REVERSE (Resynchro-
zation Reverses Remodeling in Systolic Left Ventricular
ysfunction), and MIRACLE ICD II (Multicenter InSync
D Randomized Clinical Evaluation II), all of which are
scussed in the following paragraphs (20–22,58).
MADIT-CRT (20) randomized patients with NYHA class
or II ischemic and NYHA class II nonischemic cardiomy-
athy, LVEF30%, and QRS duration130 ms on GDMT
CRT-D or ICD alone. Of note, only 15% of the total cohort
patients were NYHA class I. The primary endpoint, a
mposite of death or HF event, was reduced by 34% by
RT-D (HR: 0.66), with comparable benefit for both isch-
ic and nonischemic etiology of HF. HF events were
duced by 41%, without significant reduction in mortality
te. CRT-D therapy was demonstrated to be of more benefit
women than in men (HR: 0.37 and 0.76, respectively) and
patients with QRS duration 150 ms than in patients with
RS duration 150 ms (HR: 0.48 and 1.06, respectively)
0). Patients with LBBB had a significant reduction in
ntricular tachycardia, ventricular fibrillation, and death
mpared to non-LBBB patients, who derived no benefit
R: 0.47 and 1.24, respectively) (10).
RAFT (21) reported the use of CRT-D in patients with
YHA class II or class III ischemic or nonischemic cardio-
yopathy, LVEF 30%, and QRS duration 120 ms, as
mpared to those treated with an ICD alone. The primary
tcome of death or hospitalization for HF occurred in 33%
patients receiving CRT-D and in 40% of patients receiving
D only. RAFT not only showed a significant reduction in
spitalization for HF (HR: 0.68; 95% CI: 0.56 to 0.83;
0.001) but also was the first study to show a statistically
gnificant reduction in death (HR: 0.75; 95% CI: 0.62 to
91; p0.003) in mildly symptomatic patients with NYHA
ass II symptoms. However, CRT-D was associated with a
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ications at 30 days after implantation (p0.001) compared
ith an ICD and no CRT. Patients with LBBB had a better
tcome than did non-LBBB patients, but the statistical
teraction between benefit and QRS morphology was weak
this trial (p0.046). CRT-D therapy was effective in
tients with QRS duration 150 ms but of no benefit in
tients with QRS duration 150 ms (HR for QRS
ration 150 ms: 0.59; 95% CI: 0.48 to 0.73; HR for
RS duration 150 ms: 0.99; 95% CI: 0.77 to 1.27;
0.002 for interaction). Thus, both MADIT-CRT and
AFT showed benefit in NYHA class II patients treated with
RT-D and demonstrated that the benefit was primarily
hieved in patients with QRS duration 150 ms and LBBB
0,21).
The REVERSE trial consisted of 610 patients. This study
sessed CRT-D therapy in patients with NYHA class I or II
F symptoms on maximum medical therapy, LVEF 40%,
d QRS duration 120 ms followed for 12 months and
owed that 16% of patients receiving CRT and 21% without
RT worsened (p0.10). The time to first HF hospitalization
as delayed in patients receiving CRT therapy (HR: 0.47).
he primary echocardiographic endpoint of ventricular re-
odeling assessed by LV end-systolic volume index was
gnificantly improved (reduction in end-systolic volume
dex) in patients treated with CRT therapy (p0.0001).
EVERSE did not report a mortality rate benefit of CRT-D
erapy (22). The lack of reported mortality rate benefit may
related to the higher ejection fraction enrollment criterion
VEF 40%) and the relatively short-term follow-up (12
onths) (22).
MIRACLE ICD II included patients with NYHA class II HF
GDMT with LVEF35% and QRS duration130 ms who
ere undergoing implantation of an otherwise indicated ICD
8). In these patients, CRT did not alter exercise capacity but
d result in significant improvement in cardiac structure and
nction and composite clinical response over 6 months.
Analysis of the multiple clinical trials of CRT is compli-
ted because trials encompass a range of LVEFs in their
try criteria, as well as a range of measured outcomes. For
ortality rate, the trials showing benefit in NYHA class III
d IV patients typically included those with LVEF 35%
2,58). For patients with NYHA class II, trials showing
ortality rate benefit included those with LVEF 30%
0,21). A mortality rate benefit with CRT has not been
own for patients who are NYHA class I (21). In terms of
monstrating improvement in cardiac function (e.g., signif-
ant reduction in LV size and improvement in ejection
action), trials have included patients with LVEF35% who
e NYHA class III and IV (58). Similarly, for patients with
VEF 40%, trials demonstrating improvement in function
ve included those who are NYHA class I and II (22). The
ngruence of results from the totality of CRT trials with
gard to remodeling and HF events provides evidence
pporting a common threshold of 35% for benefit from CRT
patients with NYHA class II through IV HF symptoms.lthough there is evidence for benefit in both CRT-D and veRT-Pacemaker patients with NYHA class III and IV symp-
ms, for NYHA class I and II HF, all of the trials tested only
RT-D and not CRT-Pacemaker, and as such, recommenda-
ons for these classes of patients can be made only for
RT-D (20–22,58).
Taken together, the evidence from the randomized trials of
RT-D in patients with reduced LVEF and NYHA class I or
shows that CRT can provide functional improvement and
crease the risk of HF events and composite outcomes
0,22,58,59). Still, CRT-D also has been shown to decrease
e mortality rate for patients with NYHA class II but not for
ose who have NYHA class I HF (20,21). As a result, the
ta support a Class I recommendation for CRT implantation
patients with LBBB and QRS duration 150 ms and
YHA class II. Because of the lack of mortality rate benefit
d smaller sample size, we believe CRT may be considered
r patients who have LVEF30%, ischemic etiology of HF,
nus rhythm, LBBB with a QRS duration 150 ms, and
YHA class I symptoms on GDMT (Class IIb; LOE: B).
For all patients, optimal outcomes with CRT require
fective placement of ventricular leads, ongoing HF manage-
ent with neurohormonal antagonists and diuretic therapy,
d in some cases, later optimization of device programming,
pecially atrioventricular (A-V) and interventricular (V-V)
tervals (51,60).
Consistent with entry criteria for studies upon which these
commendations are based, CRT implantation should be per-
rmed only when the LVEF meets guideline criteria for patients
ith nonischemic cardiomyopathy who have received 3
onths of GDMT, or for patients with ischemic cardiomyopathy
40 days after myocardial infarction receiving GDMT when
ere was no intervening revascularization, or 3 months if
vascularization was performed. It is assumed that the final
cision to recommend CRT will be based on an assessment of
VEF made after any appropriate waiting period has concluded,
ring which GDMT has been applied. Finally, the pivotal trials
monstrating the efficacy of CRT took place in centers that
ovided expertise in device and HF therapy both at implantation
d during long-term follow-up.
Two other organizational guidelines by the Heart Failure
ociety of America (61) and the European Society of Cardiology
2) have recently been published that address indications for
RT. For the patient categories in common between the Heart
ailure Society of America document and the present focused
date, there was a good deal of concordance. Although there
e many areas of agreement, some differences exist between the
esent guideline and the European Society of Cardiology
cument. One difference is that in the present guideline, CRT is
commended in NYHA class I patients who have LVEF
30%, have ischemic heart disease, are in sinus rhythm, and
ve a LBBB with a QRS duration 150 ms (Class IIb; LOE:
) (20,21). There is no similar recommendation in the European
ociety of Cardiology document. The European Society of
ardiology recommendations include patients with QRS dura-
n 120 ms. We have not recommended CRT for any
nctional class or ejection fraction with QRS durations 120
s. We also have elected to consider the presence of LBBB
rsus non-LBBB in the class of recommendations, on the basis
of
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ology, and QRS duration.
.8. Pacemaker Follow-Up
.8.3. Remote Follow-Up and Monitoring
ince the publication of the 2008 DBT guideline, important
anges have occurred related to follow-up and remote
onitoring of CIEDs (4,15,63). CIEDs include pacemakers,
Ds, CRTs, implantable loop recorders, and implantable
rdiovascular monitors. The current technology for follow-
, evidence supporting its use, and clinical practice of CIED
onitoring have evolved. Routine in-person office follow-up
pplemented by transtelephonic monitoring with limited
mote follow-up for pacemakers was the standard approach
fore 2008 (4,15). Transtelephonic monitoring, with moni-
rs that transmit the patient’s heart rhythm by converting
ectrocardiographic information to sound and transmitting it
a telephone lines to a decoding machine that then converts
e sound back into a rhythm strip, is now a dated technique
,15,63) because it allows for limited monitoring of heart
te, rhythm, and battery status of only pacemakers (63).
Contemporary remote monitoring uses bidirectional telem-
ry with encoded and encrypted radiofrequency signals,
lowing transmission and receipt of information from CIEDs
acemakers, ICDs, CRTs, implantable loop recorders, and
plantable hemodynamic monitors) (63). All major CIED
anufacturers have developed proprietary systems to allow
tients to have their devices interrogated remotely, and
any use wireless cellular technology to extend the bidirec-
onal telemetry links into the patient’s location (15,63). The
formation is analyzed, formatted, and transmitted to a
ntral server, where it can be accessed by clinicians through
e Internet. Information provided through remote follow-up
cludes virtually all of the stored information that would be
tained in an in-office visit, including battery voltage, charge
me in ICDs, percent pacing, sensing thresholds, automati-
lly measured pacing thresholds when available, pacing and
ock impedance, and stored arrhythmia events with electro-
ams (15,63). CIEDs with wireless telemetry capability may
programmed at a face-to-face evaluation to subsequently
nd automatic alerts for a variety of issues that the clinician
ems significant, such as abnormal battery voltage, abnor-
al lead parameters, or increased duration or frequency of
rhythmia episodes (15). Remote transmissions can be made
predetermined intervals or at unscheduled times for pre-
ecified alerts related to device function or activated by the
tient for clinical reasons (63). A detailed description of
chniques, indications, personnel, and frequency has been
blished as a consensus document (15).
Several prospective randomized trials have been conducted
aluating the effect of remote monitoring on clinical out-
mes (64–67) since the publication of the 2008 DBT
uideline (4). Collectively, these trials have demonstrated
at remote monitoring is a safe alternative to office visits to
aluate CIEDs. Compared with in-person office visits to
aluate CIEDs, remote monitoring leads to early discovery
clinically actionable events, decreased time to clinicalcision in response to these events, and fewer office visits O4–67). Long-term survival rates of patients monitored
motely with ICDs in a practice setting compare favorably
ith survival rates of patients in clinical trials (68).
Current suggestions for the minimum frequency of in-
fice and remote monitoring of patients with CIEDs are
mmarized in Table 3 (15). Issues such as lead malfunction,
reliable battery life indicators, and other device or lead
calls influence clinical decisions, which may change the
propriate minimum follow-up.
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Type and Frequency Method
cemaker/ICD/CRT
Within 72 h of CIED implantation In person
2–12 wk postimplantation In person
Every 3–12 mo for pacemaker/CRT-Pacemaker In person or remote
Every 3–6 mo for ICD/CRT-D In person or remote
Annually until battery depletion In person
Every 1–3 mo at signs of battery depletion In person or remote
plantable loop recorder
Every 1–6 mo depending on patient symptoms
and indication
In person or remote
plantable hemodynamic monitor
Every 1–6 mo depending on indication In person or remote
More frequent assessment as clinically indicated In person or remote
*More frequent in-person or remote monitoring may be required for all the
ove devices as clinically indicated.
CIED indicates cardiovascular implantable electronic device; CRT, cardiac
synchronization therapy; CRT-D, cardiac resynchronization therapy defibril-
tor; CRT-Pacemaker, cardiac resynchronization therapy pacemaker; and ICD,
plantable cardioverter-defibrillator.
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